Expression of ER, PR, HER2, and Cadherin tumor markers in a series of Saudi patients with BC

Abstract

OBJECTIVE: Breast cancer (BC) tumor markers have an important implication in the subsequent BC management and survival determinants. Thus, the present study aimed to formulate the expression of ER, PR, HER2, and E-cadherin tumor markers in a series of Saudi patients with BC. PATIENTS AND METHODS: About 133 BC biopsies were retrieved from the Department of Pathology at King Salman Hospital, Hai’l, Northern Saudi Arabia, from November 2019 to November 2020. Out of the 133 biopsies, 50 (37.6%) were diagnosed with BC, including 46 ductal carcinoma, 2 lobular carcinomas, and 2 papillary carcinomas. RESULTS: ER was expressed in 30/44 (68.2%), 2/2 (100%), 2/2 (100%) of the cases of DC, LC, and PC, respectively. PR was expressed in 27/43 (63%), 2/2 (100%), 2/2 (100%) of the cases of DC, LC, and PC, correspondingly. HER2 was expressed in 13/31 (42%), 0%, and 0% of DC, LC, and PC cases, respectively. Correspondingly, E-cadherin was expressed in 11/21 (52.4%), 0%, 1/1 (100%) of the cases of DC, LC, and PC. CONCLUSIONS: Triple-negative BC and HER2+ve among Saudi women are among the higher globally reported ranges, associated with poorer response to treatment and prognosis. Luckily, only one patient was found with ER-ve PR+ve, the subtype usually associated with poorer survival outcomes. E-cadherin loss is lower among Saudi BC patients, which suggests a less rate of invasion in these patients. The current study’s findings may help improve Saudi guidelines for the treatment of breast cancer.